Germany
The German market is the largest pharmaceutical market in Europe
and is the Company's largest European market in terms of revenues. In Germany, the Company markets its products through
its AWD.pharma subsidiary, whose largest selling product is Katadolon (flupirtine). Like the markets of Central and
Eastern Europe, the German market is predominantly a branded generics one, with doctors prescribing international
nonproprietary name (INN) products and corporate brands. Substitution is possible at the pharmacy level, but only
with one of the three lowest-priced generic alternatives available. All prescription drugs are reimbursed up to the
respective reference price.
In September 2007, Barr acquired O.R.C.A.pharm GmbH, a specialty
pharmaceutical company focused on the oncology market in Germany, for an initial payment of EUR 21 million in September,
a EUR 2.2 million payment in the quarter ended December 31, 2007 for working capital assumed in the transaction, and
additional payments of up to EUR 12.1 million based on the achievement of profitability milestones. This acquisition
strengthens the Company's position in the oncology market in Germany and will also allow it to add existing Barr and
PLIVA products to the O.R.C.A.pharm portfolio.
Product Guide 
